The complexities of cancer treatment can sometimes be compounded by rare neurological conditions, presenting a diagnostic challenge for physicians. A recent case highlights the importance of considering Bannwarth syndrome, a Lyme neuroborreliosis manifestation, even in patients undergoing cancer care. This syndrome, characterized by a specific set of neurological symptoms, was identified in a 72-year-classic woman with early-stage breast cancer, demonstrating that neurological deterioration in cancer patients isn’t always directly linked to the malignancy itself or its treatment.
Bannwarth syndrome, while uncommon, is a treatable cause of neurological issues. The case, detailed in reports from February 6, 2026, published by Cureus, underscores the need for a broad differential diagnosis when cancer patients experience fresh or worsening neurological symptoms. Neurological problems in individuals with breast cancer are often initially attributed to cancer metastasis, side effects of medications, or underlying neurodegenerative diseases. However, as the case illustrates, immune-mediated neuropathies like Bannwarth syndrome and Guillain-Barré syndrome should also be considered, particularly when standard imaging tests fail to provide a clear explanation. Cureus
Understanding Bannwarth Syndrome and Lyme Neuroborreliosis
Bannwarth syndrome is a relatively rare neurological complication of Lyme disease, specifically Lyme neuroborreliosis. Lyme disease is caused by the bacterium Borrelia burgdorferi, transmitted to humans through the bite of infected blacklegged ticks. While many individuals with Lyme disease experience symptoms like fever, headache, and a characteristic skin rash (erythema migrans), some develop neurological manifestations. Bannwarth syndrome specifically presents with a triad of symptoms: radicular pain (pain radiating along the course of a nerve), cranial nerve palsies (weakness or paralysis of one or more cranial nerves), and lymphocytic meningitis (inflammation of the membranes surrounding the brain and spinal cord). Medscape
The patient in the recent case presented with gradually worsening neurological symptoms following a lumpectomy for invasive ductal carcinoma. Initial investigations, including imaging studies, did not reveal any evidence of cancer spread or other obvious causes for her symptoms. This led clinicians to consider alternative diagnoses, ultimately leading to the identification of Bannwarth syndrome. The diagnosis was made through cerebrospinal fluid analysis, which revealed evidence of Lyme neuroborreliosis.
Diagnostic Challenges and the Importance of a Broad Approach
Diagnosing Bannwarth syndrome can be challenging, as its symptoms can mimic those of other neurological conditions. The overlap with potential cancer-related neurological complications further complicates the picture. The case emphasizes the importance of maintaining a high index of suspicion for less common conditions, especially when initial investigations are inconclusive. A thorough neurological examination, coupled with appropriate laboratory testing, is crucial for accurate diagnosis.
The patient’s case highlights the need for clinicians to consider immune-mediated neuropathies in cancer patients experiencing neurological symptoms. Guillain-Barré syndrome, another immune-mediated condition, shares some neurological findings with Bannwarth syndrome, further emphasizing the importance of a comprehensive diagnostic workup. Early recognition and treatment of Bannwarth syndrome are essential to prevent long-term neurological sequelae.
Treatment and Prognosis
Bannwarth syndrome is typically treated with antibiotics, specifically those effective against Borrelia burgdorferi. The duration of antibiotic therapy varies depending on the severity of the infection and the patient’s response to treatment. In the reported case, the patient responded favorably to antibiotic therapy, demonstrating the treatability of the condition. Cureus
The prognosis for patients with Bannwarth syndrome is generally fine with prompt diagnosis and treatment. However, delayed diagnosis or inadequate treatment can lead to persistent neurological deficits. The case underscores the importance of raising awareness among healthcare professionals about this rare but treatable condition, particularly in the context of cancer care.
As research continues, a deeper understanding of the interplay between cancer, its treatment, and the immune system will be crucial in optimizing the care of patients experiencing neurological complications. Further studies are needed to determine the optimal diagnostic and therapeutic strategies for Bannwarth syndrome and other immune-mediated neuropathies in cancer patients.
The medical community will continue to monitor advancements in Lyme disease diagnosis and treatment, as well as the neurological complications that can arise in cancer patients. The next update regarding research into Lyme neuroborreliosis is expected at the International Conference on Lyme Borreliosis in September 2026.
Have a question about this story or Bannwarth syndrome? Share your thoughts in the comments below, and please share this article with your network.
